Laureate Pharma Appoints Kathleen P. Bloch as Chief Financial Officer

PRINCETON, N.J., Dec. 13, 2010 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announces the addition of Kathleen P. Bloch as Chief Financial Officer. Ms. Bloch's primary objective is to increase capital and provide a platform for the continued growth of Laureate Pharma. Her plans include the development of a robust, interactive financial reporting systems, including a project-facing system and a materials management system that will further client relationships.

As CFO she is responsible for finance, accounting and information technology activities in addition to serving as a member of the Company's Management Committee. Ms. Bloch has taken direct responsibility for Laureate's relationships with banks, insurance companies, accounting firms and other external business vendors as well as relationships with law firms and investors.

"Kathy brings more than 20 years executive financial experience to Laureate and she has managed growth and driven performance in rapidly-expanding manufacturing environments," said Michael A. Griffith, Chief Executive Officer of Laureate. "She possesses the knowledge and expertise required to lead Laureate Pharma as we invest and grow."

Since 2007 Ms. Bloch was employed by PC Group, Inc., where she served as Chief Operating Officer and Chief Financial Officer. Prior to this, Ms. Bloch managed day-to-day operations for The Silverman Group, a real estate and investment company. For ten years prior she was employed by Silver Line Building Products Corporation, a leading privately-held manufacturer of vinyl windows. She served as CFO from 1999 until 2006 when the company was acquired by Andersen Corporation, a leading manufacturer of windows. She holds a Master of Business Administration degree and a Bachelor of Science Accounting degree from LaSalle University.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical contract development and manufacturing organization. Laureate's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing and regulatory support. Laureate has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.

About Saints Capital, LLC

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Pharma, at (609) 919-3367, or [email protected]  or visit www.laureatepharma.com or Jennifer Vollaro at Integrated Marketing Services at (609) 683.9055 ext. 247, or [email protected].

SOURCE Laureate Pharma, Inc.